Chemed Raises Full-Year EPS Guidance and Executes Substantial Share Repurchase

summarizeSummary

Chemed reported Q1 results, officially raised its full-year adjusted EPS guidance, and executed a significant $197.7 million share repurchase, signaling strong operational performance and capital allocation.

check_boxKey Events

• Raised Full-Year EPS Guidance

  Chemed increased its full-year 2026 adjusted diluted EPS guidance to a revised range of $24.00 to $24.75, up from the original $23.25 to $24.25, primarily driven by strong VITAS performance.

• Significant Share Repurchase

  The company repurchased 500,000 shares of its stock for $197.7 million during the first quarter, with approximately $229.6 million remaining under its existing share repurchase authorization.

• Strong VITAS Performance

  The VITAS Healthcare segment reported a 3.1% increase in net patient revenue to $420.0 million and a 6.9% increase in admissions, leading to an upward revision in its full-year ADC and revenue growth outlook.

• Strategic Roto-Rooter Acquisitions

  Roto-Rooter acquired two franchises for an aggregated $20.6 million, which are anticipated to add $5.0 million to $5.5 million in revenue for the remainder of 2026.

auto_awesomeAnalysis

This 8-K details Chemed's first-quarter results, which include strong performance from its VITAS segment and a significant share repurchase. While the Q1 results were previously reported by news, the company has now officially raised its full-year adjusted EPS guidance, reflecting an improved operational outlook, particularly for VITAS. The substantial share repurchase demonstrates management's confidence and commitment to shareholder value, making this a notable capital allocation event.